KALA BIO is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of therapies for diseases of the eye. Co.'s product candidate, KPI-012, is a mesenchymal stem cell secretome (MSC-S) and is in clinical development for the treatment of persistent corneal epithelial defects, a rare disease of impaired corneal healing. In addition, Co. has initiated preclinical studies under its KPI-014 program to evaluate the utility of its MSC-S platform for inherited retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. The KALA YTD return is shown above.
The YTD Return on the KALA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether KALA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KALA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|